Clinical use of topical thrombin as a surgical hemostat

Biologics: Targets and Therapy

Volumn 2, Issue 4, 2008, Pages 593-599

  Lew, Wesley K ^a   Weaver, Fred A ^b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Antibodies; Antigenicity; Bovine; Human; Recombinant; Thrombin

Indexed keywords

EID: 70349266541     PISSN: 11775475     EISSN: 11775491     Source Type: Journal    
DOI: None     Document Type: Review

References (47)

1. Adams JD, Jones S, Brost BC. 2001. Development of antibodies to topical bovine thrombin after abdominal hysterectomy. A case report. J Reprod Med, 46:909-12.
2. Banninger H, Hardegger T, Tobler A, et al. 1993. Fibrin glue in surgery: frequent development of inhibitors of bovine thrombin and human factor V. Br J Haematol, 85:528-32.
3. Baxter. Packet Insert for Floseal. Last updated March 2005. URL: http://www.baxter.com/products/biopharmaceuticals/downloads/ FloSeal_PI.pdf.
4. Baxter. Packet Insert for Tisseal. Last updated February 2007. URL: http://www.baxter.com/products/biopharmaceuticals/downloads/ Tisseel_PI.pdf.
5. Berruyer M, Amiral J, Ffrench P, et al. 1993. Immunization by bovine thrombin used with fibrin glue during cardiovascular operations. Development of thrombin and factor V inhibitors. J Thorac Cardiovasc Surg, 105:892-7.
6. Brister SJ, Ofosu FA, Buchanan MR. 1994. Thrombin: its key role in thrombogenesis: implications for its inhibition clinically. Boca Raton, FL: CRC Press.
7. Canonico S. 2003. The use of human fibrin glue in the surgical operations. Acta Biomed, 74(Suppl 2):21-5.
8. Chapman WC, Lockstadt H, Singla N, et al. 2006. Phase 2, randomized, double-blind, placebo-controlled, multicenter clinical evaluation of recombinant human thrombin in multiple surgical indications. J Thromb Haemost, 4:2083-5.
9. Chapman WC, Singla N, Genyk Y, et al. 2007. A phase 3, randomized, double-blind comparative study of the efficacy and safety of topical recombinant human thrombin and bovine thrombin in surgical hemostasis. J Am Coll Surg, 205:256-65.
10. Dahlback B. 2000. Blood coagulation. Lancet, 355:1627-32.
11. Flaherty MJ, Henderson R, Wener MH. 1989. Iatrogenic immunization with bovine thrombin: a mechanism for prolonged thrombin times after surgery. Ann Intern Med, 111:631-4.
12. Fastenau DR, Hormuth DA, McIntyre JA. 1999. Antiphospholipid antibodies in left-ventricular assist system recipients after exposure to topical bovine thrombin. Transplant Proc, 31:141-2.
13. Frantz VK, Clarke HT, Lattes R. 1944. Hemostasis with absorbable gauze (oxidized cellulose). Ann Surg, 120:181-98.
14. Glickman M, Gheissari A, Money S, et al. 2002. A polymeric sealant inhibits anastomotic suture hole bleeding more rapidly than gelfoam/thrombin: results of a randomized controlled trial. Arch Surg, 137:326-31; discussion 332.
15. Heffernan JK, Ponce RA, Zuckerman LA, et al. 2007. Preclinical safety of recombinant human thrombin. Regul Toxicol Pharmacol, 47:48-58.
16. Israels SJ, Israels ED. 1994. Development of antibodies to bovine and human factor V in two children after exposure to topical bovine thrombin. Am J Pediatr Hematol Oncol, 16:249-54.
17. Israels SJ, Leaker MT. 1997. Acquired inhibitors to factors V and X after exposure to topical thrombin: interference with monitoring of low molecular weight heparin and warfarin. J Pediatr, 131:480-3.
18. Jackson MR. 2001. Fibrin sealants in surgical practice: An overview. Am J Surg, 182:1S-7S.
19. Johnson and Johnson Wound Management. Packet Insert for Evicel. Last updated June 2007. URL: http://www.vapr.com/public/USENG/ EVICEL_EPI.pdf.
20. Kajitani M, Ozdemir A, Aguinaga M, et al. 2000. Severe hemorrhagic complication due to acquired factor V inhibitor after single exposure to bovine thrombin product. J Card Surg, 15:378-82.
21. King Pharmaceuticals Inc. Package Insert for Thrombin-JMI. Last updated September 2007, URL: http://www.kingpharm.com/kingpharm/ uploads/pdf_inserts/Thrombin_Web_PI_2007-09.pdf.
22. Lawson JH, Pennell BJ, Olson JD, et al. 1990. Isolation and characterization of an acquired antithrombin antibody. Blood, 76:2249-57.
23. Lawson JH, Lynn KA, Vanmatre RM, et al. 2005. Antihuman factor V antibodies after use of relatively pure bovine thrombin. Ann Thorac Surg, 79:1037-8.
24. Lawson JH. 2006. The clinical use and immunologic impact of thrombin in surgery. Semin Thromb Hemost, 32(Suppl 1):98-110.
25. Muntean W, Zenz W, Finding K, et al. 1994. Inhibitor to factor V after exposure to fibrin sealant during cardiac surgery in a two-year-old child. Acta Paediatr, 83:84-7.
26. Omrix Biopharmaceuticals. Packet Insert for Evithrom. Last updated 2007. URL: http://www.fda.gov.libproxy.usc.edu/cber/label/ evithromLB.pdf.
27. Ortel TL, Charles LA, Keller FG, et al. 1994. Topical thrombin and acquired coagulation factor inhibitors: clinical spectrum and laboratory diagnosis. Am J Hematol, 45:128-135.
28. Ortel TL, Mercer MC, Thames EH, et al. 2001. Immunologic impact and clinical outcomes after surgical exposure to bovine thrombin. Ann Surg, 233:88-96.
29. Patterson C, Stouffer GA, Madamanchi N, et al. 2001. New tricks for old dogs: nonthrombotic effects of thrombin in vessel wall biology. Circ Res, 88:987-97.
30. Pavlovich CP, Battiwalla M, Rick ME, et al. 2001. Antibody induced coagulopathy from bovine thrombin use during partial nephrectomy. J Urol, 165:1617.
31. Poynton AR, Nelson MC, McCance SE, et al. 2003. Bovine thrombin induces an acquired coagulopathy in sensitized patients undergoing revision spinal surgery: a report of two cases. Spine, 28:E221-3.
32. Rapaport SI, Zivelin A, Minow RA, et al. 1992. Clinical significance of antibodies to bovine and human thrombin and factor V after surgical use of bovine thrombin. Am J Clin Pathol, 97:84-91.
33. Sabel M, Stummer W. 2004. The use of local agents: Surgicel and Surgifoam. Eur Spine J, 13(Suppl 1):S97-101.
34. Sands JJ, Nudo SA, Ashford RG, et al. 2000. Antibodies to topical bovine thrombin correlate with access thrombosis. Am J Kidney Dis, 35:796-801.
35. Sarfati MR, Dilorenzo DJ, Kraiss LW, et al. 2004. Severe coagulopathy following intraoperative use of topical thrombin. Ann Vasc Surg, 18:349-51.
36. Savage WJ, Kickler TS, Takemoto CM. 2007. Acquired coagulation factor inhibitors in children after topical bovine thrombin exposure. Pediatr Blood Cancer, 49:1025-9.
37. Schoenecker JG, Johnson RK, Lesher AP, et al. 2001. Exposure of mice to topical bovine thrombin induces systemic autoimmunity. Am J Pathol, 159:1957-69.
38. Schwartz M, Madariaga J, Hirose R, et al. 2004. Comparison of a new fibrin sealant with standard topical hemostatic agents. Arch Surg, 139:1148-54.
39. Spero JA. 1993. Bovine thrombin-induced inhibitor of factor V and bleeding risk in postoperative neurosurgical patients. Report of three cases. J Neurosurg, 78:817-20.
40. Streiff MB, Ness PM. 2002. Acquired FV inhibitors: a needless iatrogenic complication of bovine thrombin exposure. Transfusion, 42:18-26.
41. Taylor LM, Jr, Mueller-Velten G, Koslow A, et al. 2003. Prospective randomized multicenter trial of fibrin sealant versus thrombinsoaked gelatin sponge for suture-or needle-hole bleeding from polytetrafluoroethylene femoral artery grafts. J Vasc Surg, 38:766-71.
42. Timmerman L. Bloomberg News. FDA allows ZymoGenetics to skip trial of spray drug, saving time and money. March 7, 2007, URL: http://seattletimes.nwsource.com/html/biotech/2003605976_ webzymo07.html.
43. U.S. Food and Drug Administration. FDA News. August 28, 2007. URL: http://www.fda.gov/bbs/topics/NEWS/2007/NEW01690.html.
44. Wagner WR, Pachence JM, Ristich J, et al. 1996. Comparative in vitro analysis of topical hemostatic agents. J Surg Res, 66:100-8.
45. Weaver F, Lew W, Granke K, et al. 2008. A comparison of recombinant thrombin to bovine thrombin as a hemostatic ancillary in patients undergoing peripheral artery bypass and arteriovenous graft procedures. in press.
46. Zehnder JL, Leung LL. 1990. Development of antibodies to thrombin and factor V with recurrent bleeding in a patient exposed to topical bovine thrombin. Blood, 76:2011-6.
47. Zymogenetics. Packet Insert for Recothrom. Last updated January 2008.